Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN7075 and Cemiplimab in Advanced Solid Tumors
NCT04626635Phase 2Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2020
- Primary completion
- Nov 2026
- Countries
- 7
01
Overview
Phase 2, open-label trial of dalmitamig in solid tumor (11 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Dose-Limiting Toxicities at 6 weeks, Treatment-Emergent Adverse Events at 5 years and 4 more. Started Dec 2020; status: active, not recruiting.
02
Drugs
dalmitamig
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04626635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04626635.